Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market
Executive Summary
At $19,500 per year, Radius Health's Tymlos (abaloparatide) is priced to compete with Lilly's similar, but well-established drug Forteo. The company hopes to increase the size of the osteoporosis market to achieve its blockbuster sales goal, but at least one analyst has her doubts.
You may also be interested in...
Radius Business Review Ends In Sale To Investment Funds
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.
Finance Watch: DRI Healthcare’s Canadian IPO Enables More Royalty Deals
Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.
Amgen Launches Evenity For High-Risk Osteoporosis At $21,900 List Price
Amgen EVP Murdo Gordon highlighted the unmet need for women at high risk, including those with a prior fracture. At $1,825 per month or $21,900 for a one-year course in the US, he says Evenity's cost is much lower versus competing 18- and 24-month anabolic agents.